Hologic — Q1 2024 Earnings Presentation
45 slides from Hologic's earnings presentation, Feb 1, 2024
Slide 1: The New Hologic: Bigger. Faster. Stronger.
The New Hologic Bigger. Faster. Stronger. February 2024 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or other
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this presentation: constant currency revenues; organic revenues; organic revenues excluding COVID-19, non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective t
Slide 4: Presentation Outline
Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 4
Slide 5: Investment Thesis: The New Hologic
Investment Thesis: The New Hologic • Overview: ○ Purpose Driven. Results Driven. ○ Engaged and dependable • Bigger: ○ A larger company, with more durable revenue • Faster: ○ An improved projected growth algorithm: 5 to 7% ○ Diversified contributions • Stronger: ○ Exceptionally strong balance sheet ○
Slide 6: Purpose Driven.
Purpose Driven. The Hologic Virtuous Circle Championing Women's Health • The Hologic Global Women’s Health Index • Project Health Equity • Global Access Initiative • WTA Partnership Driving Core Growth & Creating New Markets 6
Slide 7: Purpose Driven. Results Driven.
Purpose Driven. Results Driven. The Hologic Virtuous Circle Financial Profile • Projected 5 to 7% Organic ex. COVID* Revenue Growth • Strong Margin Profile • Entire P&L Utilized for EPS Growth • Fortress Balance Sheet 7 *Organic revenue excludes revenue from divested businesses and revenue from acqu
Slide 8: Board of Directors
Board of Directors Steve MacMillan Sally W. Crawford Charles J. Dockendorff Scott Garrett Stacey D. Stewart Nanaz Mohtashami Namal Nawana Christiana Stamoulis Amy M. Wendell Ludwig N. Hantson 8
Slide 9: Our Engaged and Exceptional Teams…
Our Engaged and Exceptional Teams… A Highly Engaged A Great Place to Work Workforce • 95% - “When I look at what we Gallup Q12 Survey Results accomplish, I feel a sense of pride” 100% 96% 96% 96% 97% 83% • 95% - “I’m proud to tell others I work 80% 73% here” 63% 64% 60% • 93% - “I feel good about th
Slide 10: …Grow and Drive Dependable Financial Results.
…Grow and Drive Dependable Financial Results. • 15.6% • Delivered mid-teens Organic ex. COVID growth in FY23, with initial guidance of LDD • All three franchises achieved double-digit growth 10 Note: Organic revenue excludes the divested Blood Screening business and revenue from acquisitions held fo
Slide 11: …Grow and Drive Dependable Financial Results.
…Grow and Drive Dependable Financial Results. • 15.6% • Delivered mid-teens Organic ex. COVID growth in FY23, with initial guidance of LDD • All three franchises achieved double-digit growth • $1.9 Billion • Cash on our balance sheet at the end of Q1’24 11 Note: Organic revenue excludes the divested
Slide 12: …Grow and Drive Dependable Financial Results.
…Grow and Drive Dependable Financial Results. • 15.6% • Delivered mid-teens Organic ex. COVID growth in FY23, with initial guidance of LDD • All three franchises achieved double-digit growth • $1.9 Billion • Cash on our balance sheet at the end of Q1’24 • 11 Quarters • Consistently delivered on robu
Slide 13: …Grow and Drive Dependable Financial Results.
…Grow and Drive Dependable Financial Results. • 15.6% • Delivered mid-teens Organic ex. COVID growth in FY23, with initial guidance of LDD • All three franchises achieved double-digit growth • $1.9 Billion • Cash on our balance sheet at the end of Q1’24 • 11 Quarters • Consistently delivered on robu
Slide 14: Poised for Future Success.
Poised for Future Success. • Bigger, Faster, Stronger • Forged during COVID and macro volatility • Fortified balance sheet to continue strong capital deployment • Well positioned to maximize opportunity and realize potential 14
Slide 15: You Can Count on Us to Deliver.
You Can Count on Us to Deliver. • An Excellent Start to FY’24 with Organic ex. COVID estimated growth in HSD’s on an average selling days basis Q1’23 Q1’24 Revenue Change (CC) Revenue Diagnostics $447.8 $559.3 (20.6%) Organic Diagnostics ex. $388.1 $387.7 (0.9%) COVID Organic Molecular $268.1 $260.9
Slide 16: Presentation Outline
Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 16
Slide 17: Hologic is a Bigger and more Durable Company Post Pandemic.
Hologic is a Bigger and more Durable Company Post Pandemic. • Maximized opportunities through macro volatility; significant potential ahead Total Hologic Global Revenue Organic ex. COVID-19* $4,000 $3,624 $3,500 $3,000 $2,876 $2,500 $2,000 $1,500 $1,000 $500 $0 2019 2023 Note: Dollars in millions. *
Slide 18: In Diagnostics we are More than 40% Larger
In Diagnostics we are More than 40% Larger and in Molecular Diagnostics we are 80% Larger… Global Diagnostics Revenue Organic ex. COVID-19* Global Molecular Diagnostics Revenue Organic ex. COVID-19* $1,600 $1,478 $998 $1,000 $1,400 $1,200 $800 $1,029 $1,000 $600 $557 $800 $600 $400 $400 $200 $200 $0
Slide 19: …Leveraging a Significantly Expanded Panther Footprint…
…Leveraging a Significantly Expanded Panther Footprint… Global Panther Installed Base 3,500 ~3,260 3,000 2,500 2,000 ~1,700 1,500 1,000 500 0 2019 2023 19
Slide 20: …And Continuing to Innovate.
…And Continuing to Innovate. • Genius Digital Diagnostics System CE Marked, Now FDA Cleared February 2024 o Highlighting our focus on workflow automation and AI 20
Slide 21: In Breast Health we are Nearly 10% Larger with More Recurring Revenue.
In Breast Health we are Nearly 10% Larger with More Recurring Revenue. • A larger and more resilient franchise, delivering through supply chain headwinds Global Breast Health Revenue $1,600 $1,433 $1,400 $1,314 14% $1,200 16% 22% $1,000 19% $800 22% 29% $600 $400 36% 42% $200 $0 2019 2023 Service Ga
Slide 22: And in Surgical we are Nearly 40% Larger…
And in Surgical we are Nearly 40% Larger… Global Surgical Revenue $700 $604 $600 $500 $437 $400 $300 $200 $100 $0 2019 2023 Note: Dollars in millions. 22 ,
Slide 23: …with Increasingly Diversified Revenue.
…with Increasingly Diversified Revenue. • New growth drivers: o Less than 10% of FY19 revenue vs. more than 20% of FY23 revenue Global Surgical Revenue $604 $437 2019 2023 NovaSure Core MyoSure Fluid Management Laparoscopy Other 23 Note: Dollars in millions. New growth drivers include revenue from F
Slide 24: Presentation Outline
Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 24
Slide 25: Hologic is a Faster Growing Company Today
Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl Opportunity New Growth Drivers Strong Foundation Strong Foundation 25 Note: Organic revenue excludes revenue from divested businesses and
Slide 26: Hologic is a Faster Growing Company Today
Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl • …With New Growth Drivers, in New Markets… Opportunity • Organic + Inorganic + Market Creation • BV CV/TV, BCI, Brevera, Fluent, Accesa,
Slide 27: Hologic is a Faster Growing Company Today
Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl Intl • …With New Growth Drivers, in New Markets… Opportunity Opportunity • Organic + Inorganic + Market Creation • BV CV/TV, BCI, Brevera,
Slide 28: Hologic is a Faster Growing Company Today
Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… 5 to 7% • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, Growth MyoSure Intl Intl • …With New Growth Drivers, in New Markets… Opportunity Opportunity • Organic + Inorganic + Market Creation • BV CV/TV
Slide 29: Presentation Outline
Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 29
Slide 30: Strong Balance Sheet with Proven Commitment to Returning Capital
Strong Balance Sheet with Proven Commitment to Returning Capital Net Debt and Leverage Ratio* Diluted Shares Outstanding $4.0 $4.0 280.0 $3.5 271.3 4.6x 270.0 264.6 $3.1 259.7 $3.0 4.0x $2.8 $2.8 260.0 253.8 $2.6 $2.5 248.8 3.3x 2.8x $2.3 250.0 2.7x 2.6x $1.9 239.0 $2.0 240.0 2.3x 1.5x 230.0 0.6x 22
Slide 31: Generated $5.9 Billion in FCF over the Past 4 Years
Generated $5.9 Billion in FCF over the Past 4 Years $4.2 Billion Deployed Since FY’20 M&A Accelerates Growth • Redeployed FCF* to drive growth across • 6 deals across each division the entire P&L ○ Diagnostics • Over $1.4 billion on M&A** – Biotheranostics, Diagenode, Mobidiag ○ Breast Health • Over
Slide 32: Presentation Outline
Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 32
Slide 33: Investment Thesis: The New Hologic
Investment Thesis: The New Hologic • Overview: ○ Purpose Driven. Results Driven. ○ Engaged and dependable • Bigger: ○ A larger company, with more durable revenue • Faster: ○ An improved projected growth algorithm: 5 to 7% ○ Diversified contributions • Stronger: ○ Exceptionally strong balance sheet ○
Slide 34: Financial Overview Q1’24
Financial Overview Q1’24 Non-GAAP $M, except EPS Q1’24 ∆ vs. Q1’23 Revenue $1,013.1 (5.7%) and (6.4%) CC Organic $1,004.4 (5.5%) and (6.2%) CC Organic ex COVID $952.7 6.1% and 5.2% CC Gross Margin 60.8% (190 bps) Operating Expenses $327.3 (3.6%) Operating Margin 28.5% (260 bps) Net Margin 23.3% (160
Slide 35: 2024 & Q2’24 Financial Guidance
2024 & Q2’24 Financial Guidance 2024 Full Year* Q2’24* Guidance Guidance Revenue $3,990 – $4,065 $990 – $1,010 GAAP Diluted EPS $3.52 – $3.67 $0.77 – $0.82 Non-GAAP Diluted EPS $3.97 – $4.12 $0.95 – $1.00 • Expect fiscal 2024 organic revenue ex. COVID growth at the midpoint to be within our long-ter
Slide 36: Appendix
Appendix HOLOGIC' |
Slide 37: Hologic Overview
Hologic Overview • Revenue of $4,030 million in fiscal 2023 By Division By Type By Geography Surgical Service 15% and Other INTL 19% 24% Diagnostics Capital 47% Consumables Breast and 18% Skeletal 63% 38% US 76% Note: Percentages in pie charts are for FY23. 37
Slide 38: A Growing Base Business…
A Growing Base Business… Total Revenue* 46.5% $6,000 $5,632 -12.3% $4,863 $5,000 -16.3% -0.05% 12.1% $2,160 $4,028 5.7% $3,776 $1,431 $4,030 $60 $4,000 4.3% $248 8.3% $3,367 $3,218 5.4% $3,059 $929 $3,000 0.4% 9.9% $2,000 $1,000 $2,511 $2,705 $2,833 $2,851 $2,879 $3,052 $2,782 $3,473 $3,433 $3,782 $
Slide 39: …with Robust Profitability.
…with Robust Profitability. Non-GAAP EPS* $9.00 111.3% $8.00 $7.00 -28.4% $6.00 $5.00 63.8% -34.2% 2.3% $4.00 $3.00 9.9% 9.0% 17.4% 3.6% $2.00 14.4% -2.7% $1.00 $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02 $3.96 $4.05 $0.00 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024E Mid *Non-GA
Slide 40: COVID Assay and COVID Related Revenue
COVID Assay and COVID Related Revenue COVID Assay and COVID Related Revenue* $823 $800 $760 $700 $664 $661 $596 $600 $514 $500 $400 $365 $352 $300 $215 $187 $200 $163 $98 $100 $27 $55 $45 $52 $23 $0 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 COVID Assay Reve
Slide 41: Capitalization as of Q1’24
Capitalization as of Q1’24 Note: Dollars in millions. 41
Slide 42: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended December 30, 2023 December 31, 2022 GROSS PROFIT GAAP gross profit $567.5 $617.9 Adjustments: Amortization of acquired intangible assets 45.5 55.6 Product line discontinuance 2.8 - Non-GAAP gr
Slide 43: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended December 30, 2023 December 31, 2022 OPERATING MARGIN GAAP income from operations $198.2 $262.4 Adjustments to gross profit as detailed above 48.3 55.6 Adjustments to operating expenses as deta
Slide 44: Definitions
Definitions • Organic Revenue: Total constant currency revenue excluding the divested Blood Screening business and revenue from acquired businesses owned by Hologic for less than one year. In fiscal 2024, organic revenue excludes the divested SSI ultrasound imaging business. Revenue from acquired bu
Slide 45: For More Information:
For More Information: Ryan Simon Ryan McDowell VP, Investor Relations Director, Investor Relations ryan.simon@hologic.com ryan.mcdowell@hologic.com 45